Chief Executive Officer
Senior executive with broad experience in strategic development of advanced clinical stage biotech companies.
Chief Executive Officer
Dr. Sven Zimmermann has more than 15 years of experience in the pharmaceutical industry, and as a senior executive he successfully managed the strategic development of several advanced clinical stage biotech companies. Prior to joining Inotrem, Sven served as Chief Financial Officer at MetrioPharm, a Swiss biopharmaceutical company. He benefits from a wide ranging experience in corporate finance and capital raisings, and has been involved in several recent exits such as Novimmune’s asset sale to Swedish Orphan Biovitrum, Auris Medical’s IPO on Nasdaq as well as the acquisition of PregLem by Gedeon Richter. He began his career in the financial industry working for UBS as an Equity Analyst. He obtained a PhD in molecular biology from the University of Zurich and spent several years as a researcher in the fields of oncology, and virology.
Co-founder - Strategic R&D advisor - Consultant (former CEO 2014 – 2021)
30+ years in pharmaceutical R&D leadership with expertise in translational medicine.
Co-founder - Strategic R&D advisor - Consultant (former CEO 2014 – 2021)
Dr. Jean-Jacques Garaud is a medical doctor with over 35 years of global experience in pharmaceutical research and development in the United States and Europe. During his industry career Jean-Jacques hold positions of increasing seniority at Rhone-Poulenc Rorer, Schering-Plough, then Novartis, including Global Head of Clinical Research and Development. On moving to F Hoffmann-La Roche, Jean-Jacques became Global Head of Pharmaceutical Development and Chief Medical Officer, and lastly led Roche Pharma Research and Early Development until 2012. He became the CEO and co-founder of Inotrem in 2013. During his career he led the development and subsequent approval of many pharmaceutical products. Prior to his time in the pharmaceutical industry, Jean-Jacques practiced medicine at the Claude Bernard Hospital in Paris (Infectious Diseases and Intensive Care Medicine) after gaining his medical degree at the University of Paris.
Chief Operating Officer
Senior executive with international experience in finance and operational functions.
Chief Operating Officer
Martin Koch, COO since 2018, has a strong background in finance and operations within the pharmaceutical and biotech sectors.
As a key member of the leadership team, he supports strategic R&D decisions and manages operational aspects of projects, including planning, coordination, and resource allocation. His expertise ensures the seamless execution of complex development programs.
Chief Development Officer
Senior executive with broad international experience in drug development.
Chief Development Officer
Dr. Margarita Salcedo has worked for more than 26 years in biotech and pharma. She has a wide experience in product preclinical and clinical development as well as in precision medicine.
Margarita previously led the Translational Research at the Oncology Research and Development Unit at Servier. She also worked at the LFB, first as Head of Scientific Strategy and later as Director of the Pharmacology and Toxicology Department as well as Director of Translational Medicine where she was involved in the development and registration of therapeutic products in several indications in intensive care, oncology and hemostasis disorders
Previously, she held the positions of Project Director and Preclinical and Discovery Research Director at IDM Pharma, developing innovative cell therapies for cancer. She holds a PhD in immunology and tumor biology and is author of more than 50 peer-reviewed publications and 5 patents.
Chief Technical Officer and Head of Manufacturing
Senior executive with deep experience in development process of chemical and protein entities.
Chief Technical Officer and Head of Manufacturing
Laurent Vincens has more than 25 years of leadership experience in biologics development, large scale manufacturing and commercial launches. Before joining Inotrem, he was Head of Product Development & Production at StallergenesGreer, with oversight of the French production sites. Prior to that, he spent a decade at UCB Farchim in Switzerland where he led major projects to either create or diversify manufacturing and supply chains for marketed drugs across the EU, the United States and other markets. He started his career in GMP manufacturing at Pierre Fabre. He is an engineer and pharmacist by training; and holds a PharmD from the Faculté de Pharmacie of the Université de Lorraine, and a Master of Engineering from ENSIC in Nancy.
Co-founder & Chief Scientific Officer
Senior executive with experience in business-oriented drug discovery, translational research, and IP strategy.
Cofounder and Chief Scientific Officer
With a PhD in Immunology from the University of Lorraine under Prof. Sébastien Gibot, Marc has over 15 years of experience in immunology, discovery, and translational science in acute and chronic inflammatory diseases.
He has led pioneering research on TREM-1, having co-authored over 40 scientific publications and co-invented 9 patent. His work led to the creation of the Inotrem biotech Company, on the basis of the discovery of a first-in-class pharmacological inhibitor targeting TREM-1 and currently undergoing clinical evaluation.
Since founding Inotrem in 2013, Marc has played a central leadership role in contributing to secure over €110 million in equity and non-dilutive financing and guiding the company’s scientific and strategic direction. He oversees discovery activities, intellectual property portfolio and strategy, and plays a key role in business development activities, translational programs, development programs, biomarker strategies.
Marc also holds an Accelerated MBA from HEC buriness school (Challenge Plus program) and actively bridges science and business to drive innovation in immunotherapy.
Director of Regulatory Affairs and Quality Assurance
Senior executive with established leadership experience in worldwide Regulatory Affairs and Product Development.
Director of Regulatory Affairs and Quality Assurance
Delphine Joyeux is a Pharm D. with a Master’s Degree in International Development & Registration of Medicinal Products and more than 25 years of expertise in development and registration of pharmaceutical products in Europe and in the US. Before joining Inotrem as Regulatory Affairs and Quality Director, she held various positions as Regulatory affairs Manager and Director at Servier, Agouron (Pfizer US), Valerio Therapeutics, and Minka Therapeutics and Chief Development Officer at TridekOne.
She has a confirmed expertise of drug development across all disciplines. Delphine successfully implemented regulatory strategies and guided products through regulatory processes up to filling and approval of several marketing authorizations in Europe and new drug applications in the US.
Delphine is recognized for her rigor and ability to work within strenuous environment, to manage a team and remain focused towards strategic goals.
Global Project Director
Executive with strong international biotech/pharma R&D collaborations track record.
Global Project Director
Dr. Gregory Meiffren brings more than 15 years of experience in drug development and project leadership in biotechs.
Prior joining Inotrem, Greg was project director for the startup studio Argobio studio, where he developed the R&D programs of Laigo Bio (targeted protein degradation) and Temper Bio (inflammation), two incubated companies. Greg also served as Director of clinical development, PKPD, and biology at the biotech Adocia, translating 6 products from preclinical to clinical stage and supervising over 20 phase 1 and 2 clinical trials. He was also project leader for the two main assets of the company, developed in collaboration with Eli Lilly & Co. and with the Chinese pharma Tonghua Dongbao in the field of diabetes.
Greg holds a PhD in Immunology from the Ecole Normale Supérieure of Lyon and is inventor of 4 patent families.
Chairman of the Board
Luke Beshar is a seasoned biotechnology executive and financial expert with more than 35 years of general and financial management experience at various public and private companies.
Mr. Beshar currently serves as Chairman of the Board of Protara Therapeutics, Inc., a publicly held company focused on immuno-oncology. He also serves as director and chair of the audit committee of Omega Therapeutics. From 2014 until it was acquired by Pfizer in November 2021, he served as a director and was chair of the audit and compensation committees at Trillium Therapeutics Inc. From 2015 to 2021, Mr. Beshar served as a director and chair of audit committee of REGENXBIO Inc. Prior to this, he was Executive Vice President and Chief Financial Officer of NPS Pharmaceuticals, Inc. until it was acquired by Takeda (Shire plc), and Executive Vice President and Chief Financial Officer of Cambrex Corporation.
Mr. Beshar holds a B.S. degree in Accounting and Finance from Michigan State University, is a graduate of The Executive Program at the Darden Graduate School of Business at the University of Virginia and is a Certified Public Accountant.
Chief Executive Officer of Inotrem
Dr. Sven Zimmermann has more than 15 years of experience in the pharmaceutical industry, and as a senior executive he successfully managed the strategic development of several advanced clinical stage biotech companies. Prior to joining Inotrem, Sven served as Chief Financial Officer at MetrioPharm, a Swiss biopharmaceutical company. He benefits from a wide ranging experience in corporate finance and capital raisings, and has been involved in several recent exits such as Novimmune’s asset sale to Swedish Orphan Biovitrum, Auris Medical’s IPO on Nasdaq as well as the acquisition of PregLem by Gedeon Richter. He began his career in the financial industry working for UBS as an Equity Analyst. He obtained a PhD in molecular biology from the University of Zurich and spent several years as a researcher in the fields of oncology, and virology.
Co-founder - Strategic R&D advisor - Consultant (former CEO 2014 – 2021)
Dr. Jean-Jacques Garaud is a medical doctor with over 35 years of global experience in pharmaceutical research and development in the United States and Europe. During his industry career Jean-Jacques hold positions of increasing seniority at Rhone-Poulenc Rorer, Schering-Plough, then Novartis, including Global Head of Clinical Research and Development. On moving to F Hoffmann-La Roche, Jean-Jacques became Global Head of Pharmaceutical Development and Chief Medical Officer, and lastly led Roche Pharma Research and Early Development until 2012. He became the CEO and co-founder of Inotrem in 2013. During his career he led the development and subsequent approval of many pharmaceutical products. Prior to his time in the pharmaceutical industry, Jean-Jacques practiced medicine at the Claude Bernard Hospital in Paris (Infectious Diseases and Intensive Care Medicine) after gaining his medical degree at the University of Paris.
Independent Director
A Medical Doctor with a PhD in immunology, Thierry has acquired more than 35 years of experience in the academic sector and the pharmaceutical industry in various therapeutic fields, including oncology and inflammatory diseases. From 2014 to 2022, Thierry served as Chairman of Inotrem’s Board of Directors. He has been a Venture Partner at Andera since 2006. From 2002 to 2005, Thierry was Vice President in charge of the Oncology Therapeutic Area for Aventis (then Sanofi-Aventis). From 1998 to 2002, Thierry was Vice President (Europe) for research at Vertex Pharmaceuticals. He entered the pharmaceutical industry in 1990 at Roussel-Uclaf as Director of the Immunology Therapeutic Domain and then Scientific Director of the Health Division. Before joining the industrial sector, Thierry was responsible for the Immuno-Hematology laboratory at the Villejuif Gustave Roussy Institute, France, Director of the INSERM U333 unit dedicated to the immunology of tumors, and Professor of Immunology at the Medical University Paris XI. Thierry is the co-author of more than 120 publications in oncology, autoimmune diseases and transplantation.
Board member
Since joining Andera he has worked on numerous investments, M&As and IPOs. Raphaël has in depth experience in all types of transactions gained both in banking and in Venture Capital.
He sits on the boards of EG 427, SoniVie, ImCheck, Grey Wolf Therapeutics, Artios, AM Pharma and Exciva. He was also a board member of seevral biotech Companies until their acquisition by large pharmaceutical or medical device companies.
Raphaël began his career in London, where he spent seven years in the healthcare and investment banking industries. He was first part of the finance department of Générale de Santé International in London where he held treasury and investment analysis functions.
He subsequently worked in the healthcare groups of the Investment Banking divisions of Salomon Smith Barney (1996-1999) and Goldman Sachs (1999-2001). Raphaël participated in many M&A and capital raising deals within pharmaceuticals, medical devices, biotechnology and services companies.
Raphaël graduated from the French business school HEC in 1993 and received a Master’s in Applied Economics from Institut d’Etudes Politiques in 1994.
Board member
Dr Ena Prosser is a Partner in Fountain Healthcare Partners. Ena was part of the team that raised Fountain’s initial fund in 2008 and subsequent funds in 2014 and 2018. Ena is a PhD biotechnologist by training and has a broad background in international alliance and intellectual property management.
She led the investment in Genable Ltd (sold to Spark Therapeutics Inc in 2013), led the Series B investment in NeRRe Therapeutics Ltd and KaNDY Therapeutics Ltd, and joined the board of Inotrem S.A. (France) in 2020.
Ena was formerly Director of BioResearch Ireland at Enterprise Ireland. Prior to that, Ena held various R&D and project management roles within Elan Corporation and had extensive involvement in drug delivery development, licensing and acquisition projects over a 9-year period. Ena works closely with leading ophthalmology research charity Fighting Blindness Ireland. Ena is an Adjunct Professor at University College Dublin and a member of the Institute of Directors (Ireland).
Board member
Philippe Boucheron has more than twenty years of life science investment experience and currently serves as Deputy Chief of Life Sciences Investment at Bpifrance.
In 2000, he co-founded Bioam Funds, dedicated to early-stage life science investments, serving as Investment Manager, then, in 2004, as Managing Partner. After the merger of Bioam with CDC Entreprises in July 2010, Philippe joined the CDC Entreprises life sciences team as Investment Manager.
CDC Entreprises, FSI and Oséo merged to create Bpifrance in 2013. Since then, Philippe has served as Deputy Chief of the Life Sciences Investment Business Unit and sits on the company’s Investment Committee. He also serves on the boards of Ademtech, GamaMabs, NH Theraguix, Limflow and CorWave.
Philippe holds degrees in Biochemical Engineering and Microbial Genetics from the National Institute of Applied Sciences in Toulouse (INSA), an MSc in Biochemical Engineering from Ecole Polytechnique (Montréal, Canada) and an MBA from INSEAD.
